evoke study semaglutide Efficacy and safety of oral 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials Long-term kidney outcomes of semaglutide
Description
Semagutide is a GLP-1 agonist medication which is used to treat diabetes by keeping blood glucose under control

Information at the site cannot be used for self-treatment and self-diagnosis

10.1038/s41564-021-00880-5 129 YuX.HaoM.LiuY.MaX.LinW.XuQ.et al (2019)
The concentration-to-dose conversion table For a 1 mg/mL vial, 20 units (0.2 mL) delivers 0.2 mg of semaglutide

Adjusting the timing of injections may also help
